# A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Study · id `cardio:ct-nct06424288` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06424288](<https://clinicaltrials.gov/study/NCT06424288>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06424288

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6712 participants.

## Technical summary

Registry record NCT06424288. Randomized; triple masking; primary purpose treatment. Start 2024-06-17 (actual); primary completion 2028-05-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6712 participants (planned count; ClinicalTrials.gov record NCT06424288, source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)
- Started: 2024-06-17 (actual) (ClinicalTrials.gov record NCT06424288, source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-05-22 (anticipated) (ClinicalTrials.gov record NCT06424288, source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-05-22 (anticipated) (ClinicalTrials.gov record NCT06424288, source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Romania; Saudi Arabia; Serbia; Slovenia; South Africa; South Korea; Spain; Taiwan; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06424288, source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06424288-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
- Condition: Heart Failure
- Intervention (Drug): vicadrostat
- Intervention (Drug): empagliflozin
- Intervention (Drug): placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 89f25c14d8f5902cd4ce84cb295a6a9975b2e15ba267e404bacabfc7370f9778
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
